Toronto, Ontario--(Newsfile Corp. - August 21, 2025) - NuGen Medical Devices Inc. (NGMD:CA) ("NuGen" or the "Company"), a leader in needle-free subcutaneous drug-delivery technology, is pleased to ...

Single-use and reusable needle-free injection devices will be designed for precise self-administration and home use. PharmaJet injector pens are intended for needle-free subcutaneous delivery of a ...

The MarketWatch News Department was not involved in the creation of this content. -- PharmaJet's intramuscular (IM) Needle-free Injection System - Stratis(R) - was used to deliver Scancell's iSCIB1+ ...

CHICAGO--(BUSINESS WIRE)--Sol-Millennium® Medical Group, manufacturer of medical devices, including syringes for medication delivery and testing, is proud to announce the launch of InsuJet™ ...

CAMBRIDGE, MA, UNITED STATES, October 16, 2025 /EINPresswire.com/ -- Portal Instruments and Regeneron Publish Study Demonstrating PRIME ® Needle-Free Drug Delivery ...

(A) Dynamics of the electrically induced microbubble, showing the formation, expansion, and shrinking of the microbubble and the shock wave and microjet from the microbubble. (B) Mechanism of the ...

For a century and a half, the sharp end of a needle has been the price of admission for modern medicine. Generations of children and parents have been conditioned to […] ...

FlowBeams' needle-free injection technology could prove to be a watershed moment in healthcare and aesthetic dermatology Development of the world’s first affordable laser-based, needle-free injection ...

HONG KONG, June 19, 2025 /PRNewswire/ -- Immuno Cure BioTech ("Immuno Cure"), a clinical-stage biotechnology group based in Hong Kong Science Park, is pleased to announce its upcoming collaboration ...

FlowBeams, Enschede, The Netherlands, a medical technology spin-off from the University of Twente, has been awarded the European Innovation Council Transition grant, worth €2.5 million. The startup ...

PharmaJet’s intramuscular (IM) Needle-free Injection System - Stratis® - was used to deliver Scancell’s iSCIB1+ DNA immunotherapy in combination with immune checkpoint inhibitors in the SCOPE Phase 2 ...